Core Viewpoint - XuanZhu Bio-B (02575) saw its stock price rise over 5%, reaching a high of 71.9 HKD, approaching its historical peak of 72 HKD, driven by the inclusion of its innovative drug, Pyrocilin, in the national basic medical insurance drug list [1] Group 1: Stock Performance - The stock price of XuanZhu Bio-B increased by 4.42%, trading at 70.8 HKD with a transaction volume of 22.02 million HKD [1] Group 2: Drug Approval and Market Impact - Pyrocilin, a new CDK2/4/6 inhibitor, has shown strong efficacy in inhibiting tumor cell proliferation and was approved by the National Medical Products Administration of China for specific types of advanced or metastatic breast cancer patients in May 2025 [1] - The inclusion of Pyrocilin in the national basic medical insurance directory is expected to enhance its affordability and accessibility for patients, thereby promoting market expansion and sales growth for XuanZhu Bio-B [1] - Two approved indications for Pyrocilin have been included in the 2025 national basic medical insurance directory, and an application for its use in combination with aromatase inhibitors for first-line treatment is currently under review [1]
轩竹生物-B涨超5%逼近前高 旗下创新药轩悦宁首次纳入国家基本医保药品目录